Many investors were waiting for SS&C Technologies (ticker: SSNC) to return to organic revenue growth. The company recently checked that box in Q1 2021 and organic growth accelerated in Q2 (read more HERE). SSNC remains a relative value versus the peer group at 23x Enterprise Value to Trailing Operating Cash Flow. Further, SS&C is generating momentum in the marketplace. For example, we recently mentioned in a general article that SS&C’s AI-powered Singularity platform crossed the 50 client mark. We are also excited by SS&C’s recently announced joint venture – DomaniRx – led by SS&C Health GM Danny Delmastro. We had an in-depth conversation with Mr. Delmastro in 1H 2020 around SS&C Health’s strategy. DomaniRx is a cloud-based platform driven by an API operating model and is a good proxy for SS&C Health’s modern technology-centric strategy. For FinTech investors unfamiliar with API strategies/operating models, look no further than Stripe as perhaps the earliest example of an API-driven company. Read more about SS&C Technologies in our recent Spotlight report HERE.
You must be logged in to post a comment.